Should the patent system for new medicines be abolished?
Type
Journal articleSubject
Biomedical ResearchCommerce
Cost-Benefit Analysis
Drug Costs
Drug Industry
Financing, Government
Humans
Insurance Coverage
Legislation, Drug
Orphan Drug Production
Patents as Topic
Pharmaceutical Preparations
Public Policy
United States
Permalink
https://hdl.handle.net/10161/6721Published Version (Please cite this version)
10.1038/sj.clpt.6100393Publication Info
(2007). Should the patent system for new medicines be abolished?. Clin Pharmacol Ther, 82(5). pp. 488-490. 10.1038/sj.clpt.6100393. Retrieved from https://hdl.handle.net/10161/6721.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Henry G. Grabowski
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical
industry, government regulation of business, and the economics of innovation. His
specific interests within these fields include intellectual property and generic competition
issues, the effects of government policy actions, and the costs and returns to pharmaceutical
R&D. He has over one hundred peer reviewed articles analyzing the economics of pharmaceuticals
and also several books and monograph publica
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info